Evidence map›Paper›PMID 41042672›Full record

ArticleCell reports2025

Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma.

Alexander Frey, Kathryn Clulo, Yuewei Fei, Therese Cordero Dumit, Frankie Scallo, Jerry William Allen, Emily Chang, Curtis J Perry, Lena V Wirth, Daniel Jacobs and 7 more

Abstract read
In one paragraph

Article in Cell reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alexander FreyDepartment of Surgery, Yale School of Medicine, New Haven, CT 06511, USA.
Kathryn CluloDepartment of Medicine (Oncology), Yale School of Medicine, New Haven, CT 06511, USA.
Yuewei FeiDepartment of Medicine (Oncology), Yale School of Medicine, New Haven, CT 06511, USA.
Therese Cordero DumitDepartment of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA.
Frankie ScalloDepartment of Pathology, Yale School of Medicine, New Haven, CT 06511, USA.
Jerry William AllenDepartment of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA.
Emily ChangDepartment of Medicine (Oncology), Yale School of Medicine, New Haven, CT 06511, USA.
Curtis J PerryDepartment of Medicine (Oncology), Yale School of Medicine, New Haven, CT 06511, USA.
Lena V WirthDepartment of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA.
Daniel JacobsDepartment of Surgery, Yale School of Medicine, New Haven, CT 06511, USA.
David A BraunDepartment of Medicine (Oncology), Yale School of Medicine, New Haven, CT 06511, USA; Department of Pathology, Yale School of Medicine, New Haven, CT 06511, USA.
Marcus W BosenbergDepartment of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA; Department of Pathology, Yale School of Medicine, New Haven, CT 06511, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT 06511, USA.
Thuy T TranDepartment of Medicine (Oncology), Yale School of Medicine, New Haven, CT 06511, USA.
James CluneDepartment of Surgery, Yale School of Medicine, New Haven, CT 06511, USA.
Harriet M KlugerDepartment of Medicine (Oncology), Yale School of Medicine, New Haven, CT 06511, USA.
Kelly OlinoDepartment of Surgery, Yale School of Medicine, New Haven, CT 06511, USA. Electronic address: kelly.olino@yale.edu.
Jeffrey J IshizukaDepartment of Medicine (Oncology), Yale School of Medicine, New Haven, CT 06511, USA; Department of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA; Department of Pathology, Yale School of Medicine, New Haven, CT 06511, USA. Electronic address: jeffrey.ishizuka@yale.edu.

Funding

Yale SPORE in Skin CancerP50CA121974 · NCI · YALE UNIVERSITY · PI DAVID F STERN · 2006 to 2026
$43.9M
YALE CANCER CENTER CALABRESI IMMUNO-ONCOLOGY TRAINING PROGRAMK12CA215110 · NCI · YALE UNIVERSITY · PI Harriet M. Kluger · 2018 to 2026
$6.1M
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinomaR37CA279822 · NCI · YALE UNIVERSITY · PI David Braun · 2023 to 2026
$2.6M
Targeting dsRNA sensing and ADAR1 in melanomaR37CA279834 · NCI · YALE UNIVERSITY · PI Jeffrey J. Ishizuka · 2024 to 2026
$1.9M
Triggering Innate Immunity in Tumor Cells to Overcome Resistance to ImmunotherapyK08CA245112 · NCI · YALE UNIVERSITY · PI ISHIZUKA, JEFFREY J. · 2020 to 2024
$1.3M
NCI NIH HHS K08 CA245112NCI NIH HHS K12 CA215110NCI NIH HHS P50 CA121974NCI NIH HHS R37 CA279822NCI NIH HHS R37 CA279834
6 · The paper itself

Abstract

Although mRNA technologies have reinvigorated cancer vaccine development, the identification of strong antigens with consistent tumor cell expression and generation of durable antigen-specific CD8

Indexed as

Cancer VaccinesCarcinoma, Merkel CellInterleukin-7mRNA VaccinesSkin NeoplasmsAnimalsCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunologic MemoryMiceMice, Inbred C57BLRNA, MessengerCancer VaccinesInterleukin-7mRNA VaccinesRNA, MessengeradjuvantsCP: CancerCP: Immunologydriver antigenshuman translationIL-7Merkel cell carcinomaMerkel cell polyomavirusmRNApatient samplesT cell memoryvaccines

Identifiers

PMID41042672
PMCPMC12646823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.